Who will be blinded {17a}
This will be an unblinded study. Assessment of the primary endpoint, MAKE30, is objective and unlikely to be influenced by lack of blinding. Participating sites will be provided with their allocated pathway that will be embedded into clinical care, thus blinding is not feasible.